About
From 2014 to 2021, Dr. Maya Kalandadze was a co-investigator on phase III clinical trials — eight years inside the stage of drug testing where the endpoints are measured in patients rather than in cells. That is the unusual line in a profile that otherwise describes a long Georgian endocrinology career: a medical degree from Tbilisi State Medical University in 1996, internship training there in 1997, and more than 29 years of practice since.
She is the endocrinologist on European Fertility Clinic’s roster, a role that sits outside the cycle team and in front of it. Thyroid function, glucose handling and androgen levels are the three endocrine axes that most often decide whether a fertility workup continues or pauses, and an untreated thyroid or insulin resistance problem is a common reason an otherwise sound IVF attempt fails to implant or miscarries early. Her membership of the European Society of Endocrinology alongside the Georgian Society of Endocrinology and Metabolism places her in the guideline community that sets the thresholds for those decisions.
Trial work also changes how a physician reads a prescription. Phase III investigation means working to a protocol, with fixed doses, scheduled measures and adverse-event reporting — the discipline behind how she manages a patient’s hormone therapy across the months of a fertility plan rather than adjusting it by impression.
Clinical Expertise
- Thyroid disease in fertility planning: Hypothyroidism, subclinical thyroid dysfunction and antibody-positive thyroid disease assessed before and during treatment, where the target ranges for a woman trying to conceive differ from the general population.
- Polycystic ovary syndrome with metabolic features: Insulin resistance, weight and androgen management alongside the reproductive team’s ovulation plan.
- Insulin resistance and prediabetes: Metabolic correction as a precondition for ovulation induction or transfer, not an afterthought.
- Diabetes and pregnancy planning: Glycemic control assessment before conception, the highest-stakes part of endocrine care in ART patients.
- Other hormonal disorders: Adrenal and pituitary contributions to cycle irregularity and infertility.
- Long-term endocrine follow-up: Ongoing hormone management between cycles and after treatment ends.
Why Choose Dr. Maya Kalandadze
Eight years of phase III trial discipline. Protocol-driven medicine — fixed dosing, scheduled measurement, documented response — is what hormone management actually requires, since thyroid and metformin-type decisions are judged weeks later on a lab value, not in the room.
Two endocrine societies, one of them European. European Society of Endocrinology membership means the thresholds she applies are the ones under active European review. For patients whose prior treatment was stopped on a local reference range, that difference is worth naming.
She works the metabolic causes of infertility. PCOS and insulin resistance are the most common endocrine reason a Chinese or European patient travels to Tbilisi. Correcting the metabolic problem is frequently the step that makes an otherwise failed protocol work.
Twenty-nine years of continuity. A fertility patient may need endocrine management across several cycles and, if pregnant, into the first trimester. A physician with nearly three decades of practice is a stable point in that timeline.
Professional Affiliations
Medical degree and internship training at Tbilisi State Medical University, 1996 and 1997. Member of the Georgian Society of Endocrinology and Metabolism and of the European Society of Endocrinology. Co-investigator of phase III clinical trials from 2014 to 2021.
Suitable For
- Patients whose fertility workup found a thyroid abnormality, including subclinical cases that were left unaddressed elsewhere.
- PCOS patients with a metabolic component — insulin resistance, weight, or borderline glucose — where the reproductive plan depends on the endocrine plan.
- Women with diabetes or prediabetes who are being advised to conceive, and need glycemic assessment before that advice becomes a cycle.
- Repeated implantation failure cases where hormonal and metabolic factors have not yet been formally excluded.
- Patients needing long-term hormone management during and after assisted reproduction.